Researchers at Stanford have developed a method of preventing Graft versus Host Disease (GVHD) by inhibiting a specific immune receptor. GVHD is a major debilitating complication of transplantation.
Dr. Rosemarie DeKruyff and colleagues have generated an agonistic TIM-1 monoclonal antibody (mAb), called TIM-1 mAb 3B3. TIM-1 plays critical roles in regulating immune cell activity and is also involved in allergic response and asthma.